| Project/Area Number |
17K08751
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Human pathology
|
|---|
| Research Institution | Kurume University |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
大島 孝一 久留米大学, 医学部, 教授 (50203766)
瀬戸 加大 久留米大学, 医学部, 客員教授 (80154665)
|
|---|
| Project Period (FY) |
2017-04-01 – 2020-03-31
|
| Project Status |
Completed (Fiscal Year 2019)
|
| Budget Amount *help |
¥4,810,000 (Direct Cost: ¥3,700,000、Indirect Cost: ¥1,110,000)
Fiscal Year 2019: ¥650,000 (Direct Cost: ¥500,000、Indirect Cost: ¥150,000)
Fiscal Year 2018: ¥650,000 (Direct Cost: ¥500,000、Indirect Cost: ¥150,000)
Fiscal Year 2017: ¥3,510,000 (Direct Cost: ¥2,700,000、Indirect Cost: ¥810,000)
|
|---|
| Keywords | リンパ腫 / hTERT / hTERT promoter / PTCL-NOS / ATLL / ｈTERT / TERT promoter / HRM解析 |
|---|
| Outline of Final Research Achievements |
We investigated the effect of human telomerase reverse transcriptase (hTERT), which is closely related to telomerase activity, on the promoter mutation, protein expression frequency, and pathology in T-cell lymphoma. Gene analysis of the hTERT promoter was performed in peripheral T-cell lymphoma, nonspecific (PTCL-NOS), and angioimmunoblastic T-cell lymphoma (AITL), which are common in T-cell lymphoma. Only 2 cases of PTCL-NOS had a gene mutation, and 1 case (known mutation site) also expressed protein, but the remaining 1 case (new site) did not express protein. The mutation of hTERT promoter does not seem to be directly related to its expression. A statistical analysis of protein expression revealed that only hTERT-expressing PTCL-NOS had a significantly poor prognosis.
|
| Academic Significance and Societal Importance of the Research Achievements |
悪性リンパ腫はリンパ球（主にB 細胞、T細胞由来）が癌化したものである。末梢性T細胞リンパ腫, 非特定 (PTCL-NOS)、血管免疫芽球性 T 細胞リンパ腫 (AITL)は極めて多様性に富む疾患である。hTERTとの関連性は、ほとんど調べられていない。今回、PTCL-NOSで、hTERTタンパクを発現しているT細胞リンパ腫が予後不良であったことは、予後の層別化を行うことが可能となり、今後、そのようなPTCL-NOSに対して何らかの新しい治療法に繋がることが期待される。
|
